Alnylam RNAi Drug Reverses Progress of Rare Fatal Disease: Study

November 2, 2017

(Reuters) – More than half of patients with a rare, rapidly progressing fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology, according to results of a late stage study released on Thursday. The drug, patisiran, was being tested against the life-shortening condition called hereditary ATTR (hATTR) amyloidosis with polyneuropathy, which affects an estimated 50,000 people worldwide. It is being developed in partnership with Sanofi.

Posted by

Posted in Genetic Ethics, News, Pharma

Recommended Reading